Polycomb genes and cancer: Time for clinical application?

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 2, 2012, Pages 184-193

  Crea, Francesco ^a   Paolicchi, Elisa ^a   Marquez, Victor E ^b   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BMI1; Cancer stem cell; DZNeP; EZH2; Polycomb

Indexed keywords

3 DEAZANEPLANOCIN A; DNA METHYLTRANSFERASE INHIBITOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL RENEWAL; DRUG EFFICACY; DRUG PENETRATION; EPIGENETICS; GENE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE SILENCING; GENETIC POLYMORPHISM; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PLURIPOTENT STEM CELL; POLYCOMB GROUP GENE; PREDICTIVE VALUE; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 2; POLYCOMB-GROUP PROTEINS;

EID: 84864072835     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.10.007     Document Type: Review

References (95)

1. Dick J.E. Looking ahead in cancer stem cell research. Nat Biotechnol 2009, 27:44-46.
2. Savage P., Stebbing J., Bower M., Crook T. Why does cytotoxic chemotherapy cure only some cancers?. Nat Clin Pract Oncol 2009, 6:43-52.
3. Jirtle R.L. Epigenome: the program for human health and disease. Epigenomics 2009, 1:13-16.
4. Zorn C.S., Wojno K.J., McCabe M.T., Kuefer R., Gschwend J.E., Day M.L. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 2007, 13:2136-2143.
5. Thibault A., Figg W.D., Bergan R.C., et al. A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998, 84:87-89.
6. Even-Ram S., Yamada K.M. Of mice and men: relevance of cellular and molecular characterizations of myosin IIA to MYH9-related human disease. Cell Adhes Migr 2007, 1:152-155.
7. Ginis I., Luo Y., Miura T., et al. Differences between human and mouse embryonic stem cells. Dev Biol 2004, 269:360-380.
8. Nagase H., Ghosh S. Epigenetics: differential DNA methylation in mammalian somatic tissues. FEBS J 2008, 275:1617-1623.
9. Holliday R. Epigenetics: a historical overview. Epigenetics 2006, 1:76-80.
10. Jones P.A. Cancer. Death and methylation. Nature 2001, 409(141):3-4.
11. Crea F., Danesi R., Farrar W.L. Cancer stem cell epigenetics and chemoresistance. Epigenomics 2009, 1:63-79.
12. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
13. Mathews L.A., Crea F., Farrar W.L. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009, 78:1-17.
14. Richly H., Aloia L., Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis 2011, 2:e204.
15. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
16. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
17. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
18. Monzani E., Facchetti F., Galmozzi E., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007, 43:935-946.
19. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
20. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
21. Richardson G.D., Robson C.N., Lang S.H., Neal D.E., Maitland N.J., Collins A.T. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004, 117:3539-3545.
22. Kim C.F., Jackson E.L., Woolfenden A.E., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
23. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
24. Hurt E.M., Farrar W.L. Cancer stem cells: the seeds of metastasis?. Mol Interv 2008, 8:140-142.
25. Shipitsin M., Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008, 88:459-463.
26. Beier C.P., Beier D. CD133 negative cancer stem cells in glioblastoma. Front Biosci (Elite Ed) 2011, 3:701-710.
27. Plazas-Mayorca M.D., Bloom J.S., Zeissler U., et al. Quantitative proteomics reveals direct and indirect alterations in the histone code following methyltransferase knockdown. Mol Biosyst 2010.
28. Wiederschain D., Chen L., Johnson B., et al. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol 2007, 27:4968-4979.
29. Douglas D., Hsu J.H., Hung L., et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res 2008, 68:6507-6515.
30. Lukacs R.U., Memarzadeh S., Wu H., Witte O.N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 2010, 7:682-693.
31. Chang C.J., Yang J.Y., Xia W., et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19:86-100.
32. Suva M.L., Riggi N., Janiszewska M., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009, 69:9211-9218.
33. Herranz N., Pasini D., Diaz V.M., et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008, 28:4772-4781.
34. Umbas R., Isaacs W.B., Bringuier P.P., Xue Y., Debruyne F.M., Schalken J.A. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 1997, 74:374-377.
35. Czyzewska J., Guzinska-Ustymowicz K., Ustymowicz M., Pryczynicz A., Kemona A. The expression of E-cadherin-catenin complex in patients with advanced gastric cancer: role in formation of metastasis. Folia Histochem Cytobiol 2010, 48:37-45.
36. Dorudi S., Hanby A.M., Poulsom R., Northover J., Hart I.R. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995, 71:614-616.
37. Junxia W., Ping G., Yuan H., et al. Double strand RNA-guided endogeneous E-cadherin up-regulation induces the apoptosis and inhibits proliferation of breast carcinoma cells in vitro and in vivo. Cancer Sci 2010.
38. Du J., Li L., Ou Z., et al. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat 2011.
39. Wu Z., Lee S.T., Qiao Y., et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ 2011.
40. Xu C.R., Lee S., Ho C., et al. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis. Mol Cancer Res 2009, 7:1937-1945.
41. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
42. Crea F., Duhagon Serrat M.A., Hurt E.M., Thomas S.B., Danesi R., Farrar W.L. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer 2010.
43. Alajez N.M., Shi W., Hui A.B., et al. Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy. Cell Death Differ 2009, 16:1469-1479.
44. Qin L., Zhang X., Zhang L., et al. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 2008, 371:531-535.
45. Fujii S., Tokita K., Wada N., et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 2011.
46. Cha T.L., Zhou B.P., Xia W., et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005, 310:306-310.
47. Oldenhuis C.N., Oosting S.F., Gietema J.A., de Vries E.G. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008, 44:946-953.
48. Varambally S., Dhanasekaran S.M., Zhou M., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
49. Yu J., Rhodes D.R., Tomlins S.A., et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007, 67:10657-10663.
50. Berezovska O.P., Glinskii A.B., Yang Z., Li X.M., Hoffman R.M., Glinsky G.V. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006, 5:1886-1901.
51. Raaphorst F.M., Meijer C.J., Fieret E., et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003, 5:481-488.
52. Collett K., Eide G.E., Arnes J., et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006, 12:1168-1174.
53. Kleer C.G., Cao Q., Varambally S., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003, 100:11606-11611.
54. Lu C., Bonome T., Li Y., et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007, 67:1757-1768.
55. van Leenders G.J., Dukers D., Hessels D., et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur. Urol. 2007, 52:455-463.
56. Klarmann G.J., Hurt E.M., Mathews L.A., et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009, 26:433-446.
57. Zhang X., Wang C.X., Zhu C.B., et al. Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis. Int J Gynecol Cancer 2010, 20:1597-1603.
58. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., Gudas L.J. Increased expression of the polycomb group gene EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005, 11:8570-8576.
59. Bachmann I.M., Halvorsen O.J., Collett K., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006, 24:268-273.
60. Matsukawa Y., Semba S., Kato H., Ito A., Yanagihara K., Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006, 97:484-491.
61. Sasaki M., Ikeda H., Itatsu K., et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 2008, 88:873-882.
62. Breuer R.H., Snijders P.J., Smit E.F., et al. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 2004, 6:736-743.
63. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008, 14:6790-6796.
64. Hayry V., Tynninen O., Haapasalo H.K., et al. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 2008, 34:555-563.
65. Silva J., Garcia V., Garcia J.M., et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 2007, 9:R55.
66. van Kemenade F.J., Raaphorst F.M., Blokzijl T., et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97:3896-3901.
67. Li D.W., Tang H.M., Fan J.W., et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 2010, 136:997-1006.
68. Zhao J., Luo X.D., Da C.L., Xin Y. Clinicopathological significance of B-cell-specific Moloney murine leukemia virus insertion site 1 expression in gastric carcinoma and its precancerous lesion. World J Gastroenterol 2009, 15:2145-2150.
69. Bhattacharyya J., Mihara K., Yasunaga S., et al. BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia. Ann Hematol 2009, 88:333-340.
70. Wei Y., Xia W., Zhang Z., et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008, 47:701-706.
71. Wang H., Albadine R., Magheli A., et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol 2011.
72. Mimori K., Ogawa K., Okamoto M., Sudo T., Inoue H., Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005, 31:376-380.
73. Vrzalikova K., Skarda J., Ehrmann J., et al. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 2008, 134:1037-1042.
74. Choi Y.J., Choi Y.L., Cho E.Y., et al. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat 2009, 113:83-93.
75. Seenundun S., Rampalli S., Liu Q.C., et al. UTX mediates demethylation of H3K27me3 at muscle-specific genes during myogenesis. EMBO J 2010, 29:1401-1411.
76. Yoon K.A., Gil H.J., Han J., Park J., Lee J.S. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol 2010, 5:10-16.
77. Crea F., Fornaro L., Paolicchi E., et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol 2011.
78. Guo W.J., Zeng M.S., Yadav A., et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 2007, 67:5083-5089.
79. Wang W., Yuasa T., Tsuchiya N., et al. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance. Int J Cancer 2009, 125:2836-2843.
80. Szyf M. Epigenetics DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009, 49:243-263.
81. Tan J., Yang X., Zhuang L., et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-1063.
82. Puppe J., Drost R., Liu X., et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009, 11:R63.
83. Rao M., Chinnasamy N., Hong J.A., et al. Inhibition of histone lysine methylation enhances the expression of cancer-testis genes in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 2011.
84. Crea F., Hurt E.M., Mathews L.A., et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 2011, 10:40.
85. Yu J., Yu J., Rhodes D.R., et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007, 67:10657-10663.
86. Miranda T.B., Cortez C.C., Yoo C.B., et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009, 8:1579-1588.
87. Kwon M.J., Kim S.S., Choi Y.L., et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010, 31:974-983.
88. Coulombe R.A., Sharma R.P., Huggins J.W. Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. Eur J Drug Metab Pharmacokinet 1995, 20:197-202.
89. Fiskus W., Wang Y., Sreekumar A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
90. Karamitopoulou E., Pallante P., Zlobec I., et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer 2010, 46:1438-1444.
91. Pallante P., Terracciano L., Carafa V., et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer 2011, 46:2304-2313.
92. Crea F., Hurt E.M., Farrar W.L. Clinical significance of Polycomb gene expression in brain tumors. Mol Cancer 2010, 9:265.
93. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011, 11:135-141.
94. Kavanaugh C.J., Desai K.V., Calvo A., et al. Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res 2002, 11:617-633.
95. Crea F., Duhagon M.A., Farrar W.L., Danesi R. Pharmacogenomics and cancer stem cells: a changing landscape?. Trends Pharmacol Sci 2011.